title: [Switching to quetiapine fumarate monotherapy for treatment-resistant schizophrenia: a report of five cases].
abstract: We assessed the efficacy and tolerance of switching to monotherapy with quetiapine fumarate (QF) in treatmentresistant schizophrenia with other antipsychotics, including atypical ones. QF treatment was maintained for 8 weeks. The PANSS scores improved at least 40% over this period. QF was well tolerated without the presence of serious adverse effects. Switching to QF in these patients may therefore be considered as optimal in response and tolerance. Key words: Schizophrenia, Treatment-resistant, Antipsychotics, Quetiapine fumarate.
authors.affiliation: Unidad de Gestión Clínica de Salud Mental, Hospital Universitario de Puerto Real (Cádiz), Servicio Andaluz de Salud. tsam567@gmail.com
authors.forename: Tomás
authors.initials: T
authors.lastname: Sánchez-Araña Moreno
authors.forename: Sergio
authors.initials: S
authors.lastname: Ruiz-Doblado
authors.forename: Julián
authors.initials: J
authors.lastname: Elorza-Guisasola
authors.forename: Eulalio
authors.initials: E
authors.lastname: Valmisa-Gómez de Lara
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D008297:Male; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate